Phentermine

Summary

Phentermine (CHEMBL1574) is an approved small-molecule dopaminergic agent (ATC A08AA01); indicated across 7 conditions including obesity disorder and diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A08AA01
• Indications: 7 conditions
• Clinical trials: 39
• Chemistry: 149.23 Da · C10H15N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1574
Name	Phentermine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4771
ChEBI	CHEBI:8080
ATC	A08AA01
Molecular formula	C10H15N
Molecular weight	149.23
InChIKey	DHHVAGZRUROJKS-UHFFFAOYSA-N

SMILES: CC(C)(CC1=CC=CC=C1)N

IUPAC name: 2-methyl-1-phenylpropan-2-amine

Pharmacological roles (ChEBI): dopaminergic agent, adrenergic agent, sympathomimetic agent, appetite depressant, central nervous system stimulant, central nervous system drug.

Also known as: Duromine, Fentermina, Ionamin, NSC-759163, Phentermine, Phentermine component of qsymia, Phentermine resin, Phentermine resin 30, Phentermine resin complex, Qsiva, phentermine, PHENTERMINE

Parent form; salt/anhydrous children: CHEMBL1200912

Patent coverage: 6,906 distinct patent families (25,781 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Sodium-dependent noradrenaline transporter, Trace amine-associated receptor 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TAAR1	5.26	EC50	5470	nM	CHEMBL_ACT_2558466
SLC6A2	5.24	AC50	5725	nM	CHEMBL_ACT_25144641

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	4	MONDO:0011122	EFO:0001073
diabetes mellitus	2	MONDO:0005015	EFO:0000400
morbid obesity	2	MONDO:0005139	EFO:0001074
drug dependence	1	MONDO:0005303	EFO:0003890
liver disorder	1	MONDO:0005154	EFO:0001421
bulimia nervosa	1	MONDO:0005452	EFO:0005204
kidney disorder	1	MONDO:0005240	EFO:0003086

Clinical trials

Total trials: 39.

Phase distribution

Phase	Trials
PHASE2	11
PHASE4	10
PHASE1	8
PHASE3	4
Not specified	4
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05176626	PHASE4	ACTIVE_NOT_RECRUITING	Long-term Effectiveness of the Antiobesity Medication Phentermine
NCT05975580	PHASE4	RECRUITING	Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
NCT01886937	PHASE4	COMPLETED	Studying the Effects of Phentermine on Eating Behavior
NCT02911818	PHASE4	COMPLETED	Lifestyle Modification and Liraglutide
NCT03779048	PHASE4	COMPLETED	Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
NCT03849729	PHASE4	COMPLETED	Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery
NCT04531176	PHASE4	TERMINATED	EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
NCT04614545	PHASE4	COMPLETED	Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity
NCT05215418	PHASE4	COMPLETED	A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
NCT05579249	PHASE4	COMPLETED	A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
NCT00563368	PHASE3	COMPLETED	A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
NCT02635386	PHASE3	COMPLETED	EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
NCT03374956	PHASE3	COMPLETED	Individualized Obesity Pharmacotherapy
NCT04621929	PHASE3	COMPLETED	Phentermine/Topiramate for Uric Acid Stones
NCT06299891	PHASE2	RECRUITING	Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
NCT07282340	PHASE2	NOT_YET_RECRUITING	Phentermine’s Impact on Treatment in Teens
NCT00000506	PHASE2	COMPLETED	Cardiovascular System in Obesity: Effect of Treatment
NCT00402077	PHASE2	COMPLETED	A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
NCT00600067	PHASE2	COMPLETED	A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
NCT01950520	PHASE2	COMPLETED	Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
NCT02243202	PHASE2	COMPLETED	Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
NCT02301416	PHASE2	COMPLETED	Qsymia as an Adjunct to Surgical Therapy in the Superobese
NCT04007393	PHASE2	COMPLETED	SMART Use of Medication for the Treatment of Adolescent Severe Obesity
NCT04095104	PHASE2	COMPLETED	Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
NCT04572217	PHASE2	WITHDRAWN	Medications After Adolescent Bariatric Surgery
NCT00518466	PHASE1	COMPLETED	Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
NCT00768209	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
NCT00768404	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment
NCT01500018	PHASE1	WITHDRAWN	Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214
NCT02239913	PHASE1	COMPLETED	Topiramate-Phentermine Combinations for Cocaine Dependence
NCT02553824	PHASE1	COMPLETED	FDA Approved Medication to Reduce Binge Eating and/or Purging
NCT02609477	PHASE1	COMPLETED	A Study to Evaluate Abuse Potential of Istradefylline
NCT03152123	PHASE1	COMPLETED	Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users
NCT04881799	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity
NCT01719185	EARLY_PHASE1	COMPLETED	The Effect of Phentermine and B12 on Weight Loss Among Obese Patients
NCT05756764	Not specified	ACTIVE_NOT_RECRUITING	Anti-obesity Pharmacotherapy and Inflammation
NCT00771654	Not specified	WITHDRAWN	Phentermine/Gastric Band Weight Loss Study
NCT01616082	Not specified	COMPLETED	Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)
NCT03675191	Not specified	COMPLETED	Orlistat/Phentermine Versus Placebo/Phentermine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).